In this study of 252 patients with ER+HER2– BC and 63 patients with TNBC, we assessed the potential of computational biomarkers of both Ki67-ITH and CD8-immunogradient to predict BCSS in the context of conventional clinical, pathology, and IHC characteristics. Here, CD8A is linked to breast cancer.